Intech Investment Management LLC Buys 31,802 Shares of IDEXX Laboratories, Inc. $IDXX

Intech Investment Management LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 966.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 35,094 shares of the company’s stock after acquiring an additional 31,802 shares during the quarter. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $23,742,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Foundations Investment Advisors LLC raised its holdings in IDEXX Laboratories by 4.3% in the 4th quarter. Foundations Investment Advisors LLC now owns 897 shares of the company’s stock worth $607,000 after acquiring an additional 37 shares during the last quarter. Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $5,880,000. Huntington National Bank raised its holdings in IDEXX Laboratories by 1.8% in the 4th quarter. Huntington National Bank now owns 3,829 shares of the company’s stock worth $2,590,000 after acquiring an additional 69 shares during the last quarter. IPG Investment Advisors LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $1,499,000. Finally, Unified Investment Management purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $203,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 3.1%

IDEXX Laboratories stock opened at $568.03 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.81 billion, a P/E ratio of 41.83, a P/E/G ratio of 3.20 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The business has a 50-day simple moving average of $564.85 and a two-hundred day simple moving average of $637.70.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Piper Sandler lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Finally, UBS Group lowered their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $751.00.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.79% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.